AML treatment presents significant challenges in the elderly, who more often have poor risk cytogenetic and molecular markers, comorbidities and compromised performance status. Although population-based studies indicate that treated patients' survival is better than those who are not treated, there is an understandable reluctance of physicians to choose aggressive therapy. Even in this older population 40-60% CR rates are achievable. Several scoring systems and web-based programs help to predict TRM and CR rates. These sources can assist physicians in the difficult decision-making process of aggressive therapy in an individual patient. Clofarabine and hypomethylating agents are reasonable options and can induce CR in patients who cannot receive standard induction with anthracyclines and cytarabine. Despite encouraging CR rates, median survival remains short (o12 months) in elderly AML patients. Even those patients achieving CR have limited long-term survival (B20% at 3 years) without allogeneic hematopoietic cell transplantation (alloHCT). AlloHCT is feasible and can provide approximately 40% survival at 2 years in appropriately selected patients. Although increased age is associated with poorer survival, higher comorbidities and poor performance status have more negative impact than age per se. The short duration of CR demands that leukemia and transplant physicians collaborate immediately after diagnosis to move quickly toward alloHCT. This collaboration is also essential to choosing the right individuals to transplant and to bridging post-remission therapy (intermediate-dose cytarabine, a hypomethylating agent or FLT-3 inhibitor) in this sometimes frail population. Future studies should be designed not only to address who should receive alloHCT, but also to improve our understanding of AML biology and the process of its cure.
INTRODUCTION
AML is a curable hematologic malignancy. However, its cure requires intensive and recurrent chemotherapy cycles, and for some, the GVL effect conferred by allogeneic hematopoietic cell transplantation (alloHCT). The incidence of AML increases significantly with age; therefore, AML is predominantly a disease of the elderly. 1 The Surveillance Epidemiology and End Results (SEER) data between 2005 and 2009 indicate that the incidence of AML continuously increases with a median age of 66 years ( Figure 1 ). The common perception is that elderly patients cannot tolerate intensive therapies, which highlights the most important dilemma in AML treatment. Most patients with AML will not be treated appropriately (that is, intensively) merely because of age and therefore are incurable. Given the fact that the United States (US) population is aging (according to the 2010 US Census, there are 40.3 million people X65 years), 2 the challenge for AML treatment is expanding. Our recent analysis of US SEER data from 2000 to 2007 revealed that only 38 .6% of 5480 elderly AML patients (median age 78 years, range 65-93) received active leukemia therapy within 3 months of diagnosis. 3 This suggests that we need to challenge the status quo in AML treatment. In fact, our SEER study ( Figure 2 ) and Swedish registry data demonstrated that patients who received leukemia treatment had better survival compared to those who did not. 3, 4 Two single-center retrospective studies support these large registry data sets and show that intensive induction therapy improved survival. 5, 6 Therefore, the first hurdle is to increase the number of elderly AML patients treated after their diagnosis. AML treatment can be divided into two main phases: therapies to achieve CR (that is, induction); and postremission therapies (that is, consolidations with or without maintenance).
INDUCTION THERAPY
Issues associated with poor induction outcome Age is inversely correlated with CR rates. 7 Lower CR rates result from intrinsic biological AML-related factors, including a higher frequency of multi-drug resistance (MRD) gene overexpression, higher frequency of secondary or treatment-related AML, 8 and higher frequency of poor molecular and cytogenetic risks compared to younger patients. [8] [9] [10] [11] Lower CR rates can also be contributed by patient-related factors increasing TRM, 9 including lower performance status, 7 greater co-morbidities and lesser physiologic resilience compared to younger AML patients. Reported studies indicate that although age is important, performance status, associated comorbidities and impairment of functional status have a greater impact on survival. 12, 13 Instrumental activities of daily living (IADL) was used for analyzing the functional status of 63 AML patients (median age 61.1, with a range of 19-85 years). 12 IADL was the single most predictive variable (hazard ratio (HR): 4.3, 95% confidence interval (CI) 1.7-10.5, P ¼ 0.001) on survival. Although Karnofsky performance status (PS) (HR: 4.8, 95% CI 1.9-12.3, P ¼ 0.001) and an unfavorable cytogenetic risk group (HR:6.0, 95% CI 2.5-14.3, Po0.001) were significantly associated with survival, age did not independently affect survival. Walter et al. 13 showed that age predicted early death in 3365 AML patients (age range of 14-89) treated on various Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDACC) trials. The hematopoietic cell transplantation comorbidity index (HCT-CI) 14 has been recommended as a measure to determine whether elderly AML patients are fit for a conventional induction regimen. 15 Higher HCT-CI scores are associated with higher mortality. 12, [16] [17] [18] [19] An MDACC study in 177 elderly AML patients (age 460) showed that early date rates were 3%, 11%, and 29% in patients with HCT-CI scores of 0 (n ¼ 39), 1-2 (n ¼ 53) and X3 (n ¼ 85) (Po0.001), respectively. Median OS was inversely affected by higher HCT-CI scores (median OS was 45, 31 and 19 weeks in these three groups, P ¼ 0.04).
Is it possible to predict induction outcome?-useful models Retrospective studies in larger databases created composite models to predict outcome, in particular early death, in AML patients. 13, [20] [21] [22] [23] Various covariates including age, PS, platelet counts, albumin level, primary vs secondary AML, white blood cell count (WBC), peripheral blood blast percentage and creatinine were included in the model by Walter et al. 13 Older patients with lower TRM score (p3.9) had 1% TRM, whereas patients with higher TRM score (13.1-22.8) had 41% probability of TRM. In the British model, the Medical Research Council (MRC) AML11 trial (n ¼ 1071) was used to develop the index that included cytogenetic group, age, white blood count, PS and type of AML (de novo, secondary). 22 One-year survival rates were 53%, 43% and 16% in patients with good (score 4-6), standard (score 7-8) and poor risk groups, respectively (score X9) (Po0.0001). Interestingly, this model was applicable for patients receiving either intensive induction or non-intensive therapies. Moreover, the risk factors for survival in older AML patients were similar to those observed in younger patients. In the German group model (only for patients aged 460 years, n ¼ 1406), body temperature, age, de-novo leukemia vs leukemia secondary to cytotoxic treatment or an antecedent hematological disease, Hb, platelet count, fibrinogen and serum concentration of lactate dehydrogenase were included. In a scoring model with molecular and cytogenetic makers added to the above clinical factors as available, the probability of CR in these patients (score 1) ranged from 12% (in patients with highest score) to 91% (in patients with lowest score). The predicted risk of early TRM ranged from 6% (in patients with lowest score) to 69% (in patients with highest score). There was also a model (score 2) developed for patients whose cytogenetic and molecular characteristics were unknown. These models were also predictive of CR and early TRM. 20 An MDACC study (only for patients X70 years, n ¼ 446) found that age X80 years, complex karyotypes (X3 abnormalities), poor performance (Eastern Cooperative Oncology Group (ECOG) performance scores 2-4) and elevated creatinine were associated with high induction (8-week) mortality. Patients with none of the adverse prognostic factors had lowest TRM (16%) vs patients with X3 factors with the highest mortality (71%). 21 Although some of these models require sophisticated calculations with multiple prognostic factors, some such as the German Model provide a website where data of individual patients can be entered and calculated to determine the probabilities of TRM and CR (http://www.aml-score.org).
How to improve induction (with or without antracycline) outcomes? Despite the poor prognostic features of elderly AML patients, it is still possible to attain 40-60% of CR rates with standard anthracycline and cytarabine-based induction regimens. 24, 25 In fact, in a younger, but still elderly group (60-65 years), increased dose of DNR improved the outcome (for example, higher rates of CR (73% vs 51%), EFS (29% vs 14%) and OS (38% vs 23%)). 25 Moreover, in patients who cannot receive anthracyclinecontaining regimens, CR can be obtained with less intensive therapies ( Table 1) . In a phase III trial, 485 patients aged X65 years were randomly assigned 1:1 to receive decitabine (20 mg/m 2 daily Â 5 days every 4 weeks) versus supportive care or cytarabine (20 mg/m 2 daily Â 10 days) (control cohort) in cycles repeated every 4 weeks. 26 Patients receiving decitabine had significantly higher CR plus CR with incomplete platelet recovery (CRp) (17.8% with decitabine cohort versus 7.8% in controls (odds ratio, 2.5; 95% CI, 1.4-4.8; P ¼ 0.001) with a median time to best response of 4.3 months. CR plus CRp and CR with incomplete hematological recovery (CRi) were 27.7% in the decitabine cohort. Patients with higher ECOG PS (2 vs o2) and older patients (X70 years vs o70 years) benefited even more from decitabine. In contrast, Lubbert et al. 27 showed that although CR rates were similar, patients X75 years had lower OS. In a phase II trial giving decitabine for 10 consecutive days in 4-week repeated cycles in AML patients X60 years (n ¼ 53), CR rate was approximately 50%. 28 Decitabine was at least as effective in patients with poor-risk cytogenetics as in other cytogenetic risk groups. [26] [27] [28] [29] Clofarabine is also promising in elderly AML patients who cannot tolerate an anthracycline ( . 31 Almost half of the patients (48%) achieved a CR. Mortality rate was 18% at 30 days. Similar response rates were obtained in patients with poor cytogenetics. Lenolidomide also alone or with a hypomethylating agent has shown clinical activity in elderly AML patients. [33] [34] [35] Is achieving a CR prerequisite for long-term survival? One might ask whether achieving CR is a prerequisite for prolonged survival in elderly AML patients. Studies with limited number of patients showed that OS was longer in patients who achieved CR compared to those who did not. 30, 31, 33 However, OS even for patients in a CR was still unsatisfactory. 33 A large MDACC retrospective analysis showed poor survival in patients with CR (approximately 20% at 3 years) following intensive induction regimens, though consolidation strategies were not reported. 21 
CONSOLIDATION THERAPY IN ELDERLY AML PATIENTS
Intensive repeated consolidations (6 monthly courses of cytarabine with an antracycline) compared to one cycle of intensive consolidation as in a recent French prospective trial may yield better survival (estimated OS was 56% vs 37%). 24 However, a trial of the Cancer and Leukemia Group B (CALGB) study failed to show improved OS when mitoxantrone was added to higher doses of cytarabine (6 monthly courses) in comparison to the lower-dose cytarabine alone (4 monthly courses) in 388 elderly (X60 years) AML patients. 36 A German phase III study (n ¼ 242, median age 66 years) investigating all-trans retinoic acid (ATRA) impact on induction also compared intensive consolidations (i.v. idarubicin and etoposide) with maintenance therapy (1-year oral maintenance therapy with idarubicin and etoposide). 37 Although OS was better in patients receiving intensive consolidation, it is important to recognize that each group only included 30 patients and had intensive 3-line regimens before the randomization. In a phase III randomized trial, gemtuzumab ozogamicin consolidations did not improve the outcomes compared to no therapy. 38 Although post-remission consolidations with chemotherapies have not clearly been shown to be effective in elderly AML patients, it is possible that a subgroup of patients such as patients with core binding factor (CBF) (as in younger AML patients) might have reasonable OS with this approach. 11, 24, 39 With improvement in detection of molecular disease, we can identify patients who can benefit more from these chemotherapies (for example, patients with multi-drug resistance). Moreover, these improvements will give us opportunities of using targeted therapies. Of course, alloHCT may be the most intensive consolidation. If the Abbreviations: Ara-C ¼ cytarabine; ATRA ¼ all-trans retinoic acid; CRi ¼ CR with incomplete blood count recovery; CRp ¼ CR without full platelet recovery.
AlloHCT in elderly AML patients C Ustun et al goal of giving consolidation is to bridge alloHCT, less toxic chemotherapy should be chosen because higher dose of cytarabine consolidations before alloHCT has not improved alloHCT outcome in myeloablative 40 or RIC transplantations 41 (see below for further discussion of bridge therapy).
Current real-life problems of alloHCT in elderly AML patients The Center for International Blood and Marrow Transplant Research (CIBMTR) data indicate that hematopoietic cell transplantation, either allogeneic or autologous, has been increasingly used in patients 460 years ( Figure 3) . The primary reason for increased alloHCT in this population is that less-intensive conditioning regimens (that is, reduced-intensity conditioning (RIC) or non-myeloablative conditionings (NMAC)) resulted in successful hematopoietic engraftment with tolerable morbidity and mortality. [42] [43] [44] Despite the increasing number of alloHCTs in this group, still a very limited portion of these patients actually receive alloHCT. 2010 US census data identified 40.3 million people age 65 and older. The annual incidence of AML in patients aged 60-75 is between 7 and 15 per 100 000. Therefore, using 10/ 100 000 as an average, it is calculated that there are 4000 newly diagnosed elderly (age 60-75) AML patients per year in the US. The current (2011) number of annual alloHCT reported to the CIBMTR in this population is 242. Therefore, only B6% (242/4000) of newly diagnosed elderly AML patients are undergoing alloHCT each year (Figure 4 ).
AlloHCT outcome in elderly AML patients Though more data have been accumulating evaluating alloHCT in elderly AML patients, we still have two major problems in evaluating alloHCT outcome (Table 2) . First, only a relatively small number of alloHCT have been performed and second, that no prospective comparison with other consolidations is yet reported. Some studies have analyzed the impact of age on post-HCT mortality, mostly demonstrating that increased age did not significantly affect non-relapse mortality (NRM) or OS. [45] [46] [47] [48] McClune et al. 47 evaluated the effect of age in patients with AML and MDS. 47 Patients with AML (n ¼ 545) were divided into four cohorts by age: 40-54 years (n ¼ 201), 55-59 years (n ¼ 149), 60-64 years (n ¼ 132) and X65 years (n ¼ 63). OS rates at 2 years were similar between these four cohorts (44%, 50%, 34% and 36%, respectively, P ¼ 0.06). Age did not significantly affect NRM and PFS. In contrast, age was associated with improved neutrophil engraftment (relative risk ¼ 1.41; 95% CI, 1.14-1.76; P ¼ 0.002), as did use of RIC conditioning regimens. Risk factors associated with poor disease-free survival (DFS) or PFS were high-risk disease, 45 secondary AML following MDS, 45 unrelated donor or greater HLA disparity, 47 poor cytogenetic risk group, 47 and older donor age. 47 Risk factors reported in association with OS were higher HCT-CI scores, 46 high-risk disease, 45, 48 greater HLA-disparity, 47 KPS o80, 47 poor cytogenetic risk group, 47 mismatched unrelated donor 47 and patient/donor CMV status. 48 Some studies showed increased age was associated with more frequent GVHD. 45 Koreth et al. showed that although severe acute GVHD (aGVHD) frequencies were similar (19.1 vs 22.9%, P ¼ 0.84), chronic GVHD (cGVHD) was more frequent in patients X65 years compared to patients of 60-64 years (51.8 vs 32.5%, P ¼ 0.01). 45 Likewise, the oldest age cohort (X65 years) in the CIBMTR study had a borderline higher risk of cGVHD. 47 However, other studies found no association between increased age and GVHD. 25, 48 Some studies have indicated that pre-HCT PS has more impact than age regarding alloHCT outcome. One study showed that HCT-CI score predicted OS for all age groups. 49 Older age led to inferior NRM after alloHCT, but the effect was only minor. The findings suggested that age 440 years had an impact equivalent to a single comorbidity with a score of 1, and therefore should be assigned a score of 1 when using the HCT-CI/age composite index.
Role of umbilical cord blood (UCB) transplantation as an alternative graft source Alternative graft sources, such as UCB transplantation, were shown to be feasible and may not be inferior to unrelated adult donors in elderly patients. 50 ,51 A Japanese study including 70 patients (40% with AML) X55 years (47% of the patients were X65 years) showed an estimated PFS and OS at 2 years of 23%. The adverse effect of increasing age on outcome has been controversial. A University of Minnesota study did not show age was associated with poor OS whereas the Japanese study did (X61 years had lower OS compared to o61 years old patients. Hazard ratio [HR] for younger patients was 0.3; 95% CI: 0.14-0.72; P ¼ 0.006), along with the presence of preengraftment immune reaction, severe aGVHD or high-risk disease. Another multicenter (Minnesota, Saint-Louis, Nantes) analysis compared UCB transplantation (n ¼ 80; 70 double and 10 single UCB grafts) with matched years old. 52 The median age for all patients was 59 (range 50-74). In multivariate analysis, poor cytogenetic risk was associated with a higher rate of relapse (HR 1.7 (95% CI 1.0-3.0), P ¼ 0.04), worse LFS (HR 1.6 (1.0-2.5), P ¼ 0.03) and a trend for worse OS (HR 1.6 (1.0-2.4), P ¼ 0.06); however, donor sources had no significant impact on survival (UCB HR 1.2 (0.7-2.1), P ¼ 0.45; URD 1.2 (0.5-2.7), P ¼ 0.73 as compared to siblings). Adjusted, 3-year OS was 55% with MSD, 45% with URD and 43% with UCB (P ¼ 0.26).
We also recently reported our University of Minnesota singlecenter findings comparing UCB transplantation (n ¼ 60) with MSD alloHCT (n ¼ 38) in elderly patients with AML (approximately 70% of the patients) or MDS. 50 Median age was 61 years for UCB (range: 55-69) and 63 (range: 59-70) for MSD HCT. As expected, there were statistically significant differences in HLA full-match status (less in the UCB cohort), and anti-thymocyte globin use (higher in the UCB cohort). Other characteristics of patients and the transplantations were similar. Relapse, TRM, DFS and OS were similar. OS at 3 years was 37% for MSD and 31% for UCB recipients (P ¼ 0.21). Higher HCT-CI scores were associated with higher TRM compared with lower HCT-CI scores (relative risk: 4.0, 95% CI: 1.3-13.3, P ¼ 0.03).
Retrospective studies comparing alloHCT versus non-alloHCT consolidations Studies comparing alloHCT with other non-alloHCT consolidations in elderly AML patients in CR demonstrated favoring outcomes with alloHCT. 53, 54 AlloHCT patients (n ¼ 94) from the CIBMTR database (age 60-70 years) were matched with patients (n ¼ 96) from two CALGB trials (CALGB 9720 and CALGB 19902, in which different consolidations with or without maintenance were given). 53 To minimize time to transplantation selection bias, which might favor patients in the alloHCT cohort, the analysis was limited to patients who remained in CR1 for at least 4 months. UCB transplantations and MAC regimens were excluded. AlloHCT patients were slightly younger (medians: 63 vs 65 years, Po0.01) and had a longer time from diagnosis to CR1 (median 44 vs 38 days; P ¼ 0.031). Sex distribution, proportion of therapy-related leukemia, white blood cell count at diagnosis, FAB subtype, or proportions of patients with favorable, normal, intermediate-II, or adverse-risk karyotypes were similar between these cohorts. AlloHCT was associated with significantly lower risk of relapse (32% vs 81% at 3 years, Po0.001), but higher NRM (36% vs 4% at 3 years, Po0.001), and longer leukemia-free survival (32% vs 15% at 3 years; P ¼ 0.001). AlloHCT led to improved OS, which did not reach statistical significance (37% vs 25% at 3 years, P ¼ 0.08). In the Japan registry, AML patients in CR1 aged 50-70 years and receiving (n ¼ 152) alloHCT or chemotherapy (n ¼ 884) were compared, 54 including haploidentical, UCB grafts and MAC regimens in alloHCT cohort. Patients who received alloHCT in CR1 were younger (median, 55 vs 61 years, Po0.001) and had more unfavorable characteristics than those treated with non-HCT consolidation. AlloHCT patients had less frequent good-risk cytogenetics (3% vs 18%, Po0.001) and longer time to reach CR1 (48 vs 39 days, Po0.001), more frequent marrow dysplasia (49% vs 22%, Po0.001), but less frequent high WBC 420 Â 10 9 /L (18% vs 35%, Po0.001). The cumulative incidence of relapse in the alloHCT group was significantly lower than that in the chemotherapy group (22% vs 62%). Both OS and relapse-free survival (RFS) were significantly improved in the HCT group (OS: 62% vs 51%, P ¼ 0.012). Regarding retrospective studies, alloHCT seems to provide more favorable outcome compared to other consolidations in the selected population. However, the role of alloHCT will be defined with a prospective study comparing alloHCT with non-alloHCT consolidations.
Is there a prospective alloHCT study? The results of a prospective phase II trial from the Alliance and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) (CALGB 100103/BMT CTN 0502) were presented at the 2012 American Society of Hematology national meeting. 55 A total of 123 patients (60-74 years old) with AML CR1 underwent matched related transplant (47%) or matched unrelated transplant (53%) AlloHCT in elderly AML patients C Ustun et al following a RIC regimen between 2004 and 2011. Median age was 65 years. Acute severe GVHD, cGVHD and TRM were 3.4% (at 100 days), 26% (at 2 years) and 14% (at 2 years), respectively. The incidence of relapse at 2 years was 47%. At 2 years, DFS and OS were 39% and 46%, respectively. This trial suggests that alloHCT in this population is feasible, that alloHCT seems to be more effective compared to historical non-alloHCT consolidations, and that a prospective study comparing alloHCT with non-alloHCT consolidation is warranted.
Quality of life (QOL) is an end point as important as survival after alloHCT It is important to emphasize that not only prolonging survival, but also improving the QOL is a critical goal in these older patients. Deschler et al. 56 reported a QOL analysis in 160 elderly patients (age X60 years) receiving alloHCT for a hematological malignancy (111 AML patients). OS at 1 year and 3 years were 62.4% and 47.4%, respectively. A KPS of p80 was associated with markedly reduced survival (HR 2.01 (95% CI 1.27-3.18), P ¼ 0.0026). The 79 survivors were asked to complete the QLQ C30 questionnaire at last contact, after a median of 22.5 months.
The QOL values of the entire cohort were compared to the published gender-matched German reference data (age cohort 60-69 years); there were only minimally important differences. Most patients reported their QOL to be good or excellent. In fact, in the subgroup of 32 older patients (age 470), QOL values were higher than the reference values (74 vs 55 for females and 68 vs 61.5 for males). Impairment of patient functions was most prominent in their role and social functioning. The most common symptoms were fatigue, pain, dyspnea, insomnia and loss of appetite. These were more prominent in female patients. The positive interpretation of global QOL can result from, at least in part, a cognitive reappraisal of life's value as a response to a life-threatening disease. 57 To whom alloHCT should be offered in CR1 An easy answer to this very difficult question in the case of not having large data would be to define the patient group so as to not offer alloHCT with extrapolating information from the younger population. Patients with lower PS or higher HCT-CI scores 46, 47, 50 or active infection, especially invasive fungal infection, 58, 59 are expected to have poorer outcome; therefore alloHCT cannot be offered until these complications improve. Likewise, patients with active disease at the time of alloHCT have significantly higher relapse even after myeloablative alloHCT; 60, 61 therefore alloHCT's benefit will be limited after non-myeloablative/ RIC alloHCT. 62, 63 Improved OS can be observed in elderly AML patients with CBF abnormalities. 10, 25 Therefore, patients with CBF abnormalities, in particular who have neither poor prognostic molecular markers (for example, KIT mutation 64 or FLT-3 mutation 65 ) nor multi-drug resistance after first consolidation, 65 should not be offered alloHCT. Overall, patients in the favorable group as defined by the European LeukemiaNet standardized reporting system using cytogenetic and molecular genetic data, 66 which was applicable for older patients as well, 10 should not undergo alloHCT in CR1 (for example, t(8;21)(q22;q22); RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, mutated NPM1 without FLT3-ITD (normal karyotype), and mutated CEBPA (normal karyotype)).
A treatment algorithm to maximize options for alloHCT can be proposed ( Figure 5 ). In this algorithm, the first question is whether to aggressively treat an older patient with AML. In this regard, personal and institutional clinical experience for this specific population, web-based prognostic calculations and of course informed discussions with patients about potential complications, life quality and survival chances are critical in guiding decision making. AlloHCT is important and can provide curative therapy for a fraction, but is only a part of an informed therapy plan for the large older population with AML.
FUTURE DIRECTIONS
Prospective comparison of alloHCT with non-alloHCT consolidation In the US, there is no prospective trial comparing donor (alloHCT) with no donor (other consolidation therapies) not only for survival, but also for QOL and functional assessments although we have been developing an Alliance-led Intergroup study to address this question. We must emphasize, however, that the decision-making process regarding alloHCT must start at the time of diagnosis in 68 Although fewer patients in the decitabine cohort relapsed (50% vs 60%), DFS and OS were not statistically different between the two cohorts. A meta-analysis of interleukin-2 maintenance in AML showed no benefit of interleukin-2 over no treatment regarding DFS or OS. 69 After alloHCT, maintenance therapy with azacitidine was used in 45 high-risk AML patients. Azacitidine was safe when given at the dose of 32 mg/m 2 for 5 days, and EFS and OS at 1 year were 58% and 77%, respectively. 70 An ongoing phase I trial is investigating the dose and safety of quizartinib (AC220), a selective and potent FLT-3 mutation inhibitor, in this setting.
Bridging therapies between induction and alloHCT Not only inducing remission but also maintaining remission until alloHCT is done is critical in the elderly population because duration of CR is short. Post-remission intensive regimens may cause comorbidities, organ toxicities or severe infections (for example, invasive fungal infections). These complications may hinder alloHCT opportunity. Therefore, targeted consolidations can be considered as more reasonable options. In this regard, a hypomethylating drug 71, 72 or a FLT-3 inhibitor for specific subgroups will be safer and maybe more effective (an excellent review by Stone). 73 Shortening time from CR to alloHCT is essential, and alternative donor sources (UCB and haploidentical transplantation) can be found easier and faster compared with adult unrelated donors. Increasing number and experience of alternative donors will facilitate alloHCT and is a more acheivable option for elderly AML patients. Moreover, recent aggressive and successful research on in vitro stem cell expansion 74, 75 in UCB grafting may expedite neutrophil recovery-one of the major drawbacks of UCB transplantation, and thus decrease TRM. Obviously, this would be much more important for the elderly population.
